Belli Carolina, De Brasi Carlos, Larripa Irene
Departamento de Genética, Instituto de Investigaciones Hematológicas Mariano R. Castex, Academia Nacional de Medicina, Buenos Aires, Argentina.
Hum Mutat. 2003 Feb;21(2):132-7. doi: 10.1002/humu.10160.
Specific NRAS oncogene missense mutations have been frequently found in some tumors and several hematological diseases, especially in those of myeloid origin. There is a wide range of PCR-based methods for screening and detection of NRAS exon 1 single-base substitutions. However, there are disadvantages and ambiguities associated with these techniques because all of them require either separate probes, separate PCR amplifications, or complicated post-PCR manipulations. This report describes a new approach for detection of NRAS gene mutations at codon 12 and 13 based on the DNA heteroduplex analysis method. The strategy relies upon differential electrophoretic behavior of induced heteroduplex molecules formed by cross-hybridization of two PCR-amplified species, the sample under analysis and the synthetic universal heteroduplex generator (UHG). The screening of a panel of all codon 12 and 13 NRAS mutant DNA variants indicated that this approach discriminates all 12 relevant mutations. The sensitivity of the method was estimated by a competitive assay where mutant alleles could be detected at a dilution level of 1 to 16 wild-type alleles. This UHG technology was tested on some clinical samples previously studied by PCR-ASO. This methodology is highly specific, sensitive, and achieves an appreciable reduction in workload and time because it requires one PCR amplification followed by polyacrylamide gel electrophoresis in standard conditions. We propose that this new approach may be applied as an alternative strategy for codon 12-13 NRAS mutations and it could be easily incorporated into the range of routine assays performed in oncology laboratories.
特定的NRAS癌基因错义突变在一些肿瘤和几种血液系统疾病中经常被发现,尤其是在髓系起源的疾病中。有多种基于PCR的方法用于筛查和检测NRAS外显子1的单碱基替换。然而,这些技术存在缺点和不明确之处,因为它们都需要单独的探针、单独的PCR扩增或复杂的PCR后操作。本报告描述了一种基于DNA异源双链分析方法检测NRAS基因第12和13密码子突变的新方法。该策略依赖于由两个PCR扩增产物(分析样本和合成通用异源双链生成器(UHG))交叉杂交形成的诱导异源双链分子的差异电泳行为。对一组所有第12和13密码子NRAS突变DNA变体的筛查表明,该方法能够区分所有12种相关突变。通过竞争性试验估计了该方法的灵敏度,在该试验中,突变等位基因在1:16野生型等位基因的稀释水平下即可被检测到。这种UHG技术在一些先前通过PCR-ASO研究过的临床样本上进行了测试。该方法具有高度特异性、灵敏度高,并且由于只需要一次PCR扩增,然后在标准条件下进行聚丙烯酰胺凝胶电泳,从而显著减少了工作量和时间。我们建议,这种新方法可作为检测NRAS基因第12 - 13密码子突变的替代策略,并且可以很容易地纳入肿瘤学实验室进行的常规检测范围。